Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-05. Numbers and descriptions here follow the published literature rather than marketing material.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Bitcoin wallets were the first cryptocurrency wallets, enabling users to store the information necessary to transact bitcoins. The first wallet program, simply named Bitcoin, and sometimes referred to as the Satoshi client, was released in 2009 by Nakamoto as open-source software. Bitcoin Core is among the best known clients. Forks of Bitcoin Core exist such as Bitcoin Unlimited. Wallets can be full clients, with a full copy of the blockchain to check the validity of mined blocks, or lightweight clients, just to send and receive transactions without a local copy of the entire blockchain. Third-party internet services, called online wallets or hot wallets, store users' credentials on their servers, making them susceptible of hacks. Cold storage protects bitcoins from such hacks by keeping private keys offline, either through specialized hardware wallets or paper printouts.
==== Knight Grand Cross of the Order of St Michael and St George (GCMG) ==== Diplomatic Service and Overseas List Sir (Arthur) John Coles, , Permanent Under-Secretary of State, Foreign and Commonwealth Office.
Naram-Sin defeated Manium of Magan, and various northern hill tribes in the Zagros, Taurus, and Amanus Mountains, expanding his empire up to the Mediterranean Sea. His "Victory Stele" depicts his triumph over Satuni, chief of Lullubi in the Zagros Mountains. The Sumerian King List gives the length of his reign as 56 years, and at least 20 of his year-names are known, referring to military actions against various places such as Uruk and Subartu. One unknown year was recorded as "the Year when Naram-Sin was victorious against Simurrum in Kirasheniwe and took prisoner Baba the governor of Simurrum, and Dubul the ensi of Arame". Other year names refer to his construction work on temples in Akkad, Nippur, and Zabala. He also built administrative centers at Nagar and Nineveh. In general it is not possible to assign an order to Naram-Sin's year name with the exception of his first "The year Naram-Sin received a weapon of heaven/An fr[om] the temple of the god Enlil". It is, however, possible to divide them into those before his deification and after that event (assumed to be shortly after the "Great Revolt") based on the presence of a godhood determinant in his name. During his reign Naram-Sin increased direct royal control of its city-states. He maintained control over the various city-states by the simple expedient of appointing some of his many sons as key provincial governors, and his daughters as high priestesses. He also reformed the scribal system. A few loyal local governors remained in place.
In January 1877 Eddy spurned an approach from Daniel Spofford, and to everyone's surprise married another of her students, Asa Gilbert Eddy. Eddy already believed that her former student and business partner Richard Kennedy was plotting against her. Weeks after the wedding Spofford was suspected too. She had hinted in October 1876 that he might be a successor, but instead he was expelled from the Christian Scientists' Association for "immorality" after quarrelling with her over money. She filed lawsuits against him and others for royalties or unpaid tuition fees. McClure's wrote that Eddy required "absolute and unquestioning conformity" from her students. The conviction that she was at the center of plots and counter-plots became a feature of Eddy's life. She believed that several students were using what she called "malicious animal magnetism," or evil thought, against her. (She also referred to it as An. Mag., Mes., M.A.M., m.a.m., mesmerism, malicious mesmerism, animal magnetism, mental malpractice, malicious malpractice, and mental influence.) Wilson writes that the concept of malicious animal magnetism was an important one in Christian Science. In 1881 Eddy added a 46-page chapter on it, "Demonology", to Science and Health. From the 16th edition in 1886, when James Henry Wiggin became the book's editor, the chapter was reduced and renamed, and in the final edition is a seven-page chapter called "Animal Magnetism Unmasked". Eddy spoke openly about it, including to the press.
Sources: en.wikipedia.org
The carnitine shuttle is a biochemical reaction used to transport long chain fatty acids (LCFAs) from the cytosol into the matrix of the mitochondria so that they may be metabolized. While some fatty acids can, long chain fatty acids cannot pass through the mitochondrial membrane. However, carnitine (specifically its stereoisomer l-carnitine) can. The shuttle utilizes this to its advantage by attaching the LCFAs to carnitine. This new acyl-carnitine can pass through the membrane, after which it is split, with the newly separated carnitine being sent back out to shuttle more LCFAs, and the newly separated LCFAs undergoing beta oxidation to release their energy. The carnitine shuttle is an example of an antiporter system, and is a part of the broader class of metabolic reactions that constitute lipid metabolism. It is a highly conserved system found primarily in animals/some eukaryotes, although bacteria and plants still use carnitine for other things such as being an osmoprotectant, or being and electron acceptor in the electron transport chain. The shuttle system is implicated in many metabolic disorders, in the form of deficiencies of the enzymes in the system.
== See also == Bisbee Blue – Turquoise from copper mines near Bisbee, Arizona, with a deep blue color Lapis lazuli – Metamorphic rock containing lazurite, prized for its intense blue color, with a deep blue color Lazurite – Alumino-silicate mineral whose blue colour is due to a sulfide species and not copper, with a deep blue color List of minerals Variscite – Hydrated aluminium phosphate of pale green color due to trivalent chromium (Cr3+)
=== Various affinity media === Many different affinity media exist for a variety of possible uses. Briefly, they are (generalized) activated/functionalized that work as a functional spacer, support matrix, and eliminates handling of toxic reagents. Amino acid media is used with a variety of serum proteins, proteins, peptides, and enzymes, as well as rRNA and dsDNA. Avidin biotin media is used in the purification process of biotin/avidin and their derivatives. Carbohydrate bonding is most often used with glycoproteins or any other carbohydrate-containing substance; carbohydrate is used with lectins, glycoproteins, or any other carbohydrate metabolite protein. Dye ligand media is nonspecific but mimics biological substrates and proteins. Glutathione is useful for separation of GST tagged recombinant proteins. Heparin is a generalized affinity ligand, and it is most useful for separation of plasma coagulation proteins, along with nucleic acid enzymes and lipases Hydrophobic interaction media are most commonly used to target free carboxyl groups and proteins. Immunoaffinity media (detailed below) utilizes antigens' and antibodies' high specificity to separate; immobilized metal affinity chromatography is detailed further below and uses interactions between metal ions and proteins (usually specially tagged) to separate; nucleotide/coenzyme that works to separate dehydrogenases, kinases, and transaminases. Nucleic acids function to trap mRNA, DNA, rRNA, and other nucleic acids/oligonucleotides. Protein A/G method is used to purify immunoglobulins.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.